Skip to main content
. 2017 Feb 10;8(16):27635–27644. doi: 10.18632/oncotarget.15273

Table 5. Overall analysis of pathologic and oncological outcomes comparing LCA with PCA.

Outcome of interest No.of studies No.of patients
LCA/PCA
OR (95%CI) p-value Study heterogeneity
Chi2 df I2 p-value
Pathologic
 Malignancy 5 591/367 1.21[0.24,6.22] 0.82 86.38 4 95% <0.0001
 Benign 5 591/367 0.77[0.16,3.74] 0.74 83.84 4 95% <0.0001
Recurrence rate 7 756/597 0.95[0.65,1.40] 0.81 7.75 6 23% 0.26
3-year DFS 4 180/203 0.57[0.25,1.33] 0.19 2.08 2 4% 0.35
3-year OS 5 252/234 0.87[0.48,1.55] 0.63 3.23 4 0% 0.52
5-year OS 3 462/373 0.82[0.57,1.18] 0.29 1.32 2 0% 0.52
5-year RFS 3 460/295 0.83[0.56,1.22] 0.34 2.27 2 12% 0.32

LCA=laparoscopic cryoablation; PCA=percutaneous cryoablation; DFS=disease-free survival; OS=overall survival; RFS=recurrence-free survival; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval.